ibidi GmbH


    • Company type:
      • Manufacturer
      • Research & Development
    • Year founded:
    • 2001
    • Employees (at the site):
    • 42
    • Turnover range:
    • <5m EUR
    • Products/services:
    • Devices, Nanobiotechnology
      µ-Dishes, µ-Slides, and µ-Plates
      Cells & Reagents
      Software & Image Analysis

    • Core competencies:
    • ibidi develops, produces, and distributes innovative labware products, instruments, and reagents for live cell analysis and cell-based assays specifically for high end microscopy. An extensive line of cell-culture biochips—µ-Slides, µ-Dishes, and µ-Plates—offers solutions for immunofluorescence and basic cell culture, plus complex assays, such as angiogenesis, chemotaxis, wound healing, shear stress, and flow. The instrument line includes stage top incubators, plus a unique perfusion system that provides continuous flow for the simulation of blood vessels.
      Recently, ibidi launched a new system for monitoring, measuring, and controlling the O2 concentration in biological samples.
      Finally, ibidi’s newest innovation, Fuse-It reagents, allow for the efficient transport of peptides and proteins directly into the cell’s cytoplasm, within only a few minutes.
      More than 3000 publications document the extensive use of this membrane fusion technology, as well as ibidi’s other sucessful products.

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Biotechnological devices
      • Biotechnology: Biotechnological reagents
    • Industries NACE:
      • 21: Manufacture of basic pharmaceutical products and pharmaceutical preparations
      • 72: Scientific research and development
      • 72.1: Research and experimental development on natural sciences and engineering
      • 72.19: Other research and experimental development on natural sciences and engineering
    • Certification:
    • ISO 9001
      ISO 13485

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Valentin Kahl (Mr.)
      - Management